Free meningococcal vaccines tied to high-risk infusion therapy
Recorded opinion date:
The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.
What OIG Said
OIG acknowledged this is “remuneration,” but approved it due to low risk, no provider kickbacks, and FDA- driven patient safety concerns.
✓Requestor (a pharma company) offered free meningococcal vaccines to patients prescribed high-risk infusion therapies, due to a known black box risk and FDA REMS program requirements.
✓OIG said the vaccines count as “remuneration” under Anti-Kickback, and the ability to bill an admin fee also qualifies, but found the overall arrangement low risk.
✓OIG emphasized: no vaccine costs were billed to Medicare or other payors, and prescribers didn’t receive payment beyond possibly billing a ~$20 admin fee.
✓The program addressed FDA-identified gaps in REMS execution, particularly for specialists less familiar with stocking/administering meningococcal vaccines.
OIG WATCH | info@cabraconsulting.com
Diligence Checklist
What you need to be ready to show in diligence
✓Show that any free services or goods (e.g. vaccines, devices) are tied to REMS/safety compliance, not marketing or patient inducement.
✓Prove that no provider received financial gain (e.g. payments, rebates, off-books support) beyond nominal admin fees.
✓Have documentation that no vaccine or drug cost was billed to Federal programs or commercial payors.
✓Keep records showing the support is available regardless of provider choice or prescriber participation.
✓Confirm the offering is narrowly tailored to reduce a regulatory or clinical barrier, not drive product uptake.
If your patient support program offers free items or services, and you can’t show FMV alignment and compliance rationale, this is the kind of arrangement that could be flagged.
OIG WATCH | info@cabraconsulting.com
Structure not diligence-ready?
Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.
OIG WATCH | info@cabraconsulting.com
Original PDF cover text
FAVORABLE
OIG WATCH
24-11
Free meningococcal vaccines tied to high-risk infusion therapy
Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.
The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.
What OIG Said
OIG acknowledged this is “remuneration,” but approved it due to low risk, no provider kickbacks, and FDA- driven patient safety concerns.
✓Requestor (a pharma company) offered free meningococcal vaccines to patients prescribed high-risk infusion therapies, due to a known black box risk and FDA REMS program requirements.
✓OIG said the vaccines count as “remuneration” under Anti-Kickback, and the ability to bill an admin fee also qualifies, but found the overall arrangement low risk.
✓OIG emphasized: no vaccine costs were billed to Medicare or other payors, and prescribers didn’t receive payment beyond possibly billing a ~$20 admin fee.
✓The program addressed FDA-identified gaps in REMS execution, particularly for specialists less familiar with stocking/administering meningococcal vaccines.
OIG WATCH | info@cabraconsulting.com
Diligence Checklist
What you need to be ready to show in diligence
✓Show that any free services or goods (e.g. vaccines, devices) are tied to REMS/safety compliance, not marketing or patient inducement.
✓Prove that no provider received financial gain (e.g. payments, rebates, off-books support) beyond nominal admin fees.
✓Have documentation that no vaccine or drug cost was billed to Federal programs or commercial payors.
✓Keep records showing the support is available regardless of provider choice or prescriber participation.
✓Confirm the offering is narrowly tailored to reduce a regulatory or clinical barrier, not drive product uptake.
If your patient support program offers free items or services, and you can’t show FMV alignment and compliance rationale, this is the kind of arrangement that could be flagged.
OIG WATCH | info@cabraconsulting.com
Structure not diligence-ready?
Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.
OIG WATCH | info@cabraconsulting.com
Original PDF cover text
FAVORABLE
OIG WATCH 24-11
Free meningococcal vaccines tied to high-risk infusion therapy
Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.